Authors



Danielle Gentile, PhD

Latest:

Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.


Ravi Kumar Kyasaram, MS

Latest:

The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.


Jason R. Williams, MD, DABR

Latest:

Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer

Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.




Amin M. Alousi, MD

Latest:

Future Directions in Graft vs Host Disease Management

Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.


B.M. Gurupadayya

Latest:

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.





Arnab Basu, MBBS, MPH, FACP

Latest:

Future Directions in nccRCC

Panelists discuss the ongoing challenges and progress in treating non–clear cell renal cell carcinoma (nccRCC), emphasizing the need for subtype-specific trials, mechanistically driven therapy, and international collaboration to move beyond data extrapolation from clear cell RCC (ccRCC) and toward truly evidence-based, personalized care.


Leslie Bennett, MSN, RN

Latest:

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.



Mustafa Raoof, MD, MS

Latest:

PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Metastases

Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.


Steven Park, MD

Latest:

Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.


Louis Williams, MD

Latest:

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.



Maria C. Velez, MD

Latest:

Creating a Seamless Transition from Pediatric to Adult Patient Cancer Care

While there is no clear and cut way to transition patients from pediatric to adult care, Maria C. Velez, MD, has established a helpful network of willing clinicians.


Dolores Gallardo-Rincón, MD

Latest:

Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities

In this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.


Lidan Hao

Latest:

Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.


Kami Maddocks, MD

Latest:

Kami J. Maddocks, MD, Shows Optimism for Future Development of Cellular Therapies in Lymphoma

In an interview, Kami J. Maddocks, MD, details therapies that may shake up the standard of care in lymphoma going forward.




Ellen Marin, PA-C

Latest:

Clinical Scenario: AE Management for Bispecific Therapy in R/R MM

Following the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.


James Padussis, MD

Latest:

Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix

Mehmet Sitki Copur, MD, and colleagues examine the case of a 65-year-old patient with appendiceal mucinous neoplasms of the appendix who was treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.



Justine Panian, BS

Latest:

Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma

In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.



Georges Azzi, MD

Latest:

Addressing Barriers to Implementing MRD Testing in Community Oncology Practices

Minimal residual disease testing appears to be a valuable tool for predicting outcomes and potential relapse in patients with lymphoid malignancies.